Latest Breaking News On - Immagene biopharmaceuticals - Page 1 : comparemela.com

Greater percentages of patients treated with one of two doses of the novel IL-17 blocker achieved an ACR 50 response vs placebo.

United statesFrank behrensPharma advanced researchEuropean congressBoehringer ingelheimAmerican college of rheumatologyGoethe university frankfurtGilead sciences incMedscape professional networkBristol myers squibbAmerican collegePsoriasis areaSeverity indexImmagene biopharmaceuticalsTwo dosesPsoriatic arthritis